ALX Oncology Holdings Inc.
Clinical trials sponsored by ALX Oncology Holdings Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New 'Smart Bomb' drug targets Hard-to-Treat cancers in first human trial Results expected Jun 2027 (estimated)
-
New combo therapy aims to outsmart resistant breast cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding evorpacept to standard trastuzumab and chemotherapy can shrink tumors in people with metastatic HER2-positive breast cancer who have already tried the drug Enhertu. About 120 participants will receive the combination intravenously. The…
Phase 2 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New 'Smart Bomb' drug targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…
Phase 1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC